Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Gouty Arthritis (Gout) - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 23 Nov 17

The "Gouty Arthritis (Gout) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Gouty Arthritis (Gout) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 11, 1, 17, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Gouty Arthritis (Gout) - Overview
  3. Gouty Arthritis (Gout) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Gouty Arthritis (Gout) - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development
  • C&C Research Laboratories
  • CymaBay Therapeutics Inc
  • Genentech Inc
  • Immune Response BioPharma Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Monosol Rx LLC
  • Opsona Therapeutics Ltd
  • Polaris Pharmaceuticals Inc
  • Rigel Pharmaceuticals Inc
  • Swedish Orphan Biovitrum AB
  • Teijin Pharma Ltd
  • The Female Health Company
  • Wellstat Therapeutics Corp
  • XL-protein GmbH

For more information about this report visit

View source version on

Business Wire

Last updated on: 23/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.